The Clinical Impact of the Decipher Genomic Classifier in Prostate Cancer

Area of Science:

• Genomic medicine
• Oncology
• Prostate cancer research

Background:

• Traditional clinicopathologic factors inadequately capture prostate cancer heterogeneity.
• This can lead to overtreatment or undertreatment of localized prostate cancer.
• A need exists for improved tools to guide personalized treatment strategies.

Purpose of the Study:

• To evaluate the clinical utility of the Decipher genomic classifier (GC) in localized prostate cancer.
• To assess the GC's role in refining risk stratification and informing treatment decisions.
• To explore the GC's impact across different risk groups and post-treatment settings.

Main Methods:

• The Decipher GC is a 22-gene expression test.
• Its utility was assessed across various risk groups (low, intermediate, high).
• Its role in pre- and post-treatment decision-making was evaluated.

Main Results:

• The Decipher GC demonstrated clinical utility in refining risk stratification.
• It aids in identifying candidates for active surveillance in low-risk disease.
• It helps guide treatment decisions for intermediate- and high-risk prostate cancer, including post-prostatectomy management.

Conclusions:

• The Decipher GC enhances risk stratification and treatment personalization for localized prostate cancer.
• While retrospective data support its prognostic value, prospective validation is ongoing.
• Further trials will clarify its predictive utility for treatment response and optimize clinical decision-making.